Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease [0.03%]
三层 pharmacy 福利设计对慢性病患者处方购买行为的影响
Kavita V Nair,Pamela Wolfe,Robert J Valuck et al.
Kavita V Nair et al.
Objective: To evaluate the impact of 3-tier (copayment) pharmacy benefit structures on medication utilization behavior. Methods: A pret...
Daniel A Hussar
Daniel A Hussar
No funding supported the writing of this article. The author has nothing to disclose.
The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy [0.03%]
口服免疫疗法和Viaskin花生过敏治疗的有效性和价值
Jeffrey A Tice,Gregory F Guzauskas,Ryan N Hansen et al.
Jeffrey A Tice et al.
Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Sh...
Evaluating Success Factors of a Medication Adherence Tracker Pilot Program in Improving Part D Medication Adherence Metrics in a Medicare Advantage Plan: Importance of Provider Engagement [0.03%]
评估一种用药依从性跟踪试验项目对改善医疗保险优势计划中的第D部分药物依从性指标成功因素：重视医疗提供者参与的作用
Minh Hong,Tara Esse,Aisha Vadhariya et al.
Minh Hong et al.
Background: Health plans and providers can increase quality by improving adherence to chronic disease medications included in star ratings among Medicare Advantage Part D (MAPD) plan enrollees. Research is needed to evalu...
Corrections [0.03%]
更正通知书
Global Pharmaceutical Manufacturing: Association for Accessible Medicines Perspective [0.03%]
全球药品制造：促进药物普及协会的视角
David Gaugh
David Gaugh
No funding supported the writing of this article. The author has nothing to disclosed.
Harry M Lever
Harry M Lever
No funding supported the writing of this article. The author has nothing to disclose.
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer [0.03%]
larotrectinib和entrectinib二线治疗NTRK融合阳性转移性肺癌的长期疗效比较研究
Joshua A Roth,Josh J Carlson,Fang Xia et al.
Joshua A Roth et al.
Background: Larotrectinib and entrectinib are FDA-approved therapies for patients with non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase gene fusion (TRK fusion-positive) whose cancer has metas...
Pharmacy's Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging [0.03%]
药师呼吁有关部门严厉打击药价哄抬行为
T Joseph Mattingly nd,Michael D Hogue
T Joseph Mattingly nd
Early reports of potential treatment for coronavirus disease (COVID-19) have raised concerns related to pharmaceutical distribution. Despite the lack of high-quality evidence, the mere hope of effectiveness of potential treatments, such as ...
Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States [0.03%]
托法替尼治疗美国活动性银屑病关节炎的成本和健康结果相关性分析
George Bungey,Stacey Chang-Douglass,Ming-Ann Hsu et al.
George Bungey et al.
Background: Psoriatic arthritis (PsA) is a chronic progressive inflammatory condition associated with significant direct and indirect costs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Economic...